March 1, 2018, 6:00 pm - 7:30 pm
March 1, 6-7:30PM: Plenary Session with Bristol-Myers Squibb
March 2, 9AM-4PM: 1:1 Meetings with representative from Bristol-Myers Squibb. By appointment only, Apply by FEBRUARY 9, 2018 at www.lifesciencewa.org/VIPForumApp
Bristol-Myers Squibb is committed to developing transformational therapies that will lead to long-lasting remission for patients with autoimmune diseases. Our scientists are investigating novel targets within immune pathways to discover and develop truly innovative treatments and disease prevention approaches that better meet the needs of patients. Our vision for the future of cancer care is focused on researching and developing transformational oncology medicines that have the potential to raise survival expectations in a broad range of cancers and change the way patients live with cancer.
Bristol-Myers Squibb is seeking partnering opportunities in the following research areas of focus:
We are advancing the scientific understanding of Immuno-Oncology (I-O) through our extensive portfolio of investigational and approved agents. In addition to our I-O portfolio, we are investigating established non-immuno-suppressive mechanisms of action and emerging areas of cancer biology and antibody drug conjugates
We are researching novel medicines that have the potential to halt or reverse progression of tissue scarring that impacts organ function. We are currently advancing a pipeline of medicines to potentially treat multiple fibrotic diseases including nonalcoholic steatohepatitis (NASH) and idiopathic pulmonary fibrosis (IPF).
We are expanding our innovation in cardiovascular disease to focus on underserved areas with a concentration on highly validated targets. Our current research is focused on heart failure and thrombosis.
We have a pioneering, industry-leading pipeline of targets and approaches for the treatment of autoimmune diseases that includes multiple innovative, first-in-class agents in clinical development. Our current research is focused in areas of high unmet need including rheumatoid arthritis, systemic lupus erythematosus and inflammatory bowel disease.
Interested in a 1:1 Meeting? Apply by FEBRUARY 9, 2018 at www.lifesciencewa.org/VIPForumApp
More information can be found at http://www.lifesciencewa.org/event/BMSVIP